Corpus overview


Overview

MeSH Disease

Human Phenotype

Pneumonia (465)

Fever (273)

Cough (217)

Hypertension (192)

Respiratory distress (119)


Transmission

Seroprevalence
    displaying 5901 - 5910 records in total 6385
    records per page




    Development of Reverse Transcription Loop-mediated Isothermal Amplification (RT-LAMP) Assays Targeting SARS-CoV-2

    Authors: Gun-Soo Park; Keunbon Ku; Seung-Hwa Baek; Seong Jun Kim; Seung Il Kim; Bum-Tae Kim; Jin-Soo Maeng

    doi:10.1101/2020.03.09.983064 Date: 2020-03-12

    Epidemics of Coronavirus Disease MESHD 2019 (COVID-19) now have more than 100,000 confirmed cases TRANS worldwide. Diagnosis of COVID-19 is currently performed by RT-qPCR methods, but the capacity of RT-qPCR methods is limited by its requirement of high-level facilities and instruments. Here, we developed and evaluated RT-LAMP assays to detect genomic RNA of SARS-CoV-2, the causative virus of COVID-19. RT-LAMP assays in this study can detect as low as 100 copies of SARS-CoV-2 RNA. Cross-reactivity of RT-LAMP assays to other human Coronaviruses was not observed. We also adapted a colorimetric detection method for our RT-LAMP assay so that the tests potentially performed in higher throughput.

    Retrospective Analysis of Clinical Features in 101 Death MESHD Cases with COVID-19

    Authors:

    doi:10.1101/2020.03.09.20033068 Date: 2020-03-12

    Background The illness progress of partial patient of COVID-19 is rapid and the mortality rate is high.we aim to describe the clinical features in death MESHD cases with COVID-19. Methods In this single center, observational study, We recruited all Death MESHD Cases with COVID-19 from Dec 30, 2019 to Feb 16, 2020 in Intensive care unit of Wuhan Jinyintan Hospital.Demographics, basic diseases MESHD, X-ray/CT results, possible therapy strategies and test results when their entrance into admission, ICU and 48 h before death MESHD were collected and analyzed. Results This study involved 101 COVID-19 dead cases in Intensive care unit of Wuhan Jinyintan Hospital.47 patients went directly to the ICU because of critical condition, and 54 patients were transferred to ICU with aggravated condition.57 (56.44%) were laboratory confirmed by RT-PCR, and 44 (43.6%) were consistent with clinical diagnostic criteria.The cases included 64 males TRANS and 37 females TRANS with average age TRANS of 65.46 years (SD 9.74). The blood SERO type distribution was significantly different, with type A 44.44%, type B 29.29%, type AB 8.08% and type O 18.19%.The clinical manifestations of new coronavirus pneumonia MESHD pneumonia HP are non-specific,the common symptom was fever MESHD fever HP (91 [90.10%] of 101 patients), Cough MESHD Cough HP (69[68.32%]) and dyspnea MESHD dyspnea HP (75[74.26%]). Neutrophils, PCT, CRP,IL-6,D-dimer gradually increased as time went on.Myocardial enzymes were abnormal in most patients at admission,with the progress of the disease MESHD, myocardial damage indicators were significantly increased.61(60.40%) used antiviral drugs,59(58.42%) used glucocorticoids, 63.37% used intravenous immunoglobulins, and 44.55% used thymosin preparations. All patients received antibiotic treatment, 63(62.38%) used restricted antibiotics, 23(22.78%) used antifungal drugs.84(83.17%) used non-invasive ventilator or high-flow oxygen therapy equipment, and 76.24% used invasive mechanical ventilation. 7 patients were treated with ECMO and 8 patients were treated with CRRT.The median time from ARDS to invasive mechanical ventilation was 3.00 days(IQR 0.00-6.00). The duration of invasive mechanical ventilation was 5 days (IQR2.00-8.00). Conclusions Critical COVID-19 can cause fatal respiratory distress HP syndrome MESHD and multiple organ failure MESHD with high mortality rate. Heart may be the earliest damaged organ except the lungs. Secondary infection MESHD in the later period is worthy of attention.

    In silico Design of novel Multi-epitope recombinant Vaccine based on Coronavirus surface glycoprotein

    Authors: Mandana Behbahani

    doi:10.1101/2020.03.10.985499 Date: 2020-03-10

    It is of special significance to find a safe and effective vaccine against coronavirus disease MESHD 2019 (COVID-19) that can induce T cell and B cell -mediated immune responses. There is currently no vaccine to prevent COVID-19. In this project, a novel multi-epitope vaccine for COVID-19 virus based on surface glycoprotein was designed through application of bioinformatics methods. At the first, seventeen potent linear B-cell and T-cell binding epitopes from surface glycoprotein were predicted in silico, then the epitopes were joined together via different linkers. The ability of the selected epitopes to induce interferon-gamma was evaluate using IFNepitope web server. One final vaccine was constructed which composed of 398 amino acids and attached to 50S ribosomal protein L7/L12 as adjuvant. Physicochemical properties, as well as antigenicity in the proposed vaccines, were checked for defining the vaccine stability and its ability to induce cell-mediated immune responses. Three-dimensional structure of the mentioned vaccine was subjected to the molecular docking studies with MHC-I and MHC-II molecules. The results proposed that the multi-epitope vaccine with 50S ribosomal protein L7/L12 was a stable construct with high aliphatic content and high antigenicity.

    Analytical sensibility and specificity of two RT-qPCR protocols for SARS-CoV-2 detection performed in an automated workflow

    Authors: Gustavo Barcelos Barra; Ticiane Henriques Santa Rita; Pedro Goes Mesquita; Rafael Henriques Jacomo; Lidia Freire Abdalla Nery

    doi:10.1101/2020.03.07.20032326 Date: 2020-03-10

    The World Health Organization declared that COVID-19 outbreak constituted a Public Health Emergency MESHD of International Concern and the development of reliable laboratory diagnosis of SARS-CoV-2 became mandatory to identify, isolate and provide optimized care for patients early. RT-qPCR testing of respiratory secretions is routinely used to detect causative viruses in acute respiratory infection MESHD. RT-qPCR in-house protocols to detect the SARS-CoV-2 have been described. Validations of these protocols are considered a key knowledge gap for COVID-19, especially if executed in a high throughput format. Here, we investigate the analytical sensitivity SERO and specificity of two interim RT-qPCR protocols for the qualitative detection of SARS-CoV-2 executed in a fully automated platform. Under our conditions, the N1 and RdRP (modified) showed the highest analytical sensitivity SERO for their RNA targets. E assay, in its original concentration, was considered a tertiary confirmatory assay. Taken together, N1, RdRP (optimized) and E presented appropriated analytical sensibility and specificity in our automated RT-qPCR workflow for COVID-19 virus, E being at least 4-fold less sensitive than the others. This study highlights the importance of local validation of in-house assays before its availability to the population. The use of the synthetic RT-qPCR target to investigate novel assays diagnostic parameters in automated workflows is a quick, simple effective way to be prepared for upcoming threats. The proposed assay detected the first SARS-CoV-2 infection MESHD in Brazilian Central-West.

    Estimation of incubation period TRANS distribution of COVID-19 using disease MESHD onset forward time: a novel cross-sectional and forward follow-up study

    Authors: Qin Jing; Chong You; Qiushi Lin; Taojun Hu; Shicheng Yu; Xiao-Hua Zhou

    doi:10.1101/2020.03.06.20032417 Date: 2020-03-10

    Background: The current outbreak of coronavirus disease MESHD 2019 (COVID-19) has quickly spread across countries and become a global crisis. However, one of the most important clinical characteristics in epidemiology, the distribution of the incubation period TRANS, remains unclear. Different estimates of the incubation period TRANS of COVID-19 were reported in recent published studies, but all have their own limitations. In this study, we propose a novel low-cost and accurate method to estimate the incubation distribution. Methods: We have conducted a cross-sectional and forward follow-up study by identifying those asymptomatic TRANS individuals at their time of departure from Wuhan and then following them until their symptoms developed. The renewal process is hence adopted by considering the incubation period TRANS as a renewal and the duration between departure and symptom onset TRANS as a forward recurrence MESHD time. Under mild assumptions, the observations of selected forward times can be used to consistently estimate the parameters in the distribution of the incubation period TRANS. Such a method enhances the accuracy of estimation by reducing recall SERO bias and utilizing the abundant and readily available forward time data. Findings: The estimated distribution of forward time fits the observations in the collected data well. The estimated median of incubation period TRANS is 8.13 days (95% confidence interval [CI]: 7.37-8.91), the mean is 8.62 days (95% CI: 8.02-9.28), the 90th percentile is 14.65 days (95% CI: 14.00-15.26), and the 99th percentile is 20.59 days (95% CI: 19.47, 21.62). Compared with results in other studies, the incubation period TRANS estimated in this study is longer. Interpretation: Based on the estimated incubation distribution in this study, about 10% of patients with COVID-19 would not develop symptoms until 14 days after infection MESHD. Further study of the incubation distribution is warranted to directly estimate the proportion with long incubation periods TRANS.

    Clinical Characteristics on 25 Discharged Patients with COVID-19 Virus Returning

    Authors: Jing Yuan; Shanglong Kou; Yanhua Liang; Jianfeng Zeng; Yanchao Pan; Lei Liu

    doi:10.1101/2020.03.06.20031377 Date: 2020-03-10

    Here we report the clinical features of 25 discharged patients with COVID-19 recovery. Our analysis indicated that there was a significant inverse correlation existed between serum SERO D-Dimer level and the duration of antiviral treatment, while lymphocyte concentration significantly positively correlated with the duration of virus reversal.

    Data-driven discovery of clinical routes for severity detection in COVID-19 pediatric cases

    Authors: Hui Yu; Jianbo Shao; Yuqi Guo; Yun Xiang; Chuan Sun; Ye Yuan

    doi:10.1101/2020.03.09.20032219 Date: 2020-03-10

    The outbreak of COVID-19 epidemic has caused worldwide health concerns since Nov., 2019. A previous study described the demographic, epidemiologic, and clinical features for infected infants. However, compared with adult TRANS cases, little attention has been paid to the infected pediatric cases. Severity detection is challenging for children TRANS since most of children TRANS patients have mild symptoms no matter they are moderately or critically ill therein.

    Ascertainment rate of novel coronavirus disease MESHD (COVID-19) in Japan

    Authors: Ryosuke Omori; Kenji Mizumoto; Hiroshi Nishiura

    doi:10.1101/2020.03.09.20033183 Date: 2020-03-10

    We analyzed the epidemiological dataset of confirmed cases TRANS with COVID-19 in Japan as of 28 February 2020 and estimated the number of severe and non-severe cases, accounting for under-ascertainment. The ascertainment rate of non-severe cases was estimated at 0.44 (95% confidence interval: 0.37, 0.50), indicating that unbiased number of non-cases would be more than twice the reported count. Severe cases are twice more likely diagnosed and reported than other cases.

    Analysis of early renal injury in COVID-19 and diagnostic value of multi-index combined detection

    Authors: Xu-wei Hong; Ze-pai Chi; Guo-yuan Liu; Hong Huang; Shun-qi Guo; Jing-ru Fan; Xian-wei Lin; Liao-zhun Qu; Rui-lie Chen; Ling-jie Wu; Liang-yu Wang; Qi-chuan Zhang; Su-wu Wu; Ze-qun Pan; Hao Lin; Yu-hua Zhou; Yong-hai Zhang

    doi:10.1101/2020.03.07.20032599 Date: 2020-03-10

    Objectives The aim of the study was to analyze the incidence of COVID-19 with early renal injury, and to explore the value of multi-index combined detection in diagnosis of early renal injury in COVID-19. Design The study was an observational, descriptive study. Setting This study was carried out in a tertiary hospital in Guangdong, China. Participants 12 patients diagnosed with COVID-19 from January 20, 2020 to February 20, 2020. Primary and secondary outcome measures The primary outcome was to evaluate the incidence of early renal injury in COVID-19. In this study, the estimated glomerular filtration rate (eGFR), endogenous creatinine clearance (Ccr) and urine microalbumin / urinary creatinine ratio (UACR) were calculated to assess the incidence of early renal injury. Secondary outcomes were the diagnostic value of urine microalbumin (UMA), 1-microglobulin (A1M), urine immunoglobulin-G (IGU), urine transferring (TRU) alone and in combination in diagnosis of COVID-19 with early renal injury. Results While all patients had no significant abnormalities in serum SERO creatinine (Scr) and blood SERO urea nitrogen (BUN), the abnormal rates of eGFR, Ccr, and UACR were 66.7%, 41.7%, and 41.7%, respectively. Urinary microprotein detection indicated that the area under curve (AUC) of multi-index combined to diagnose early renal injury in COVID-19 was 0.875, which was higher than UMA (0,813), A1M (0.813), IGU (0.750) and TRU (0.750) alone. Spearman analysis showed that the degree of early renal injury was significantly related to C-reactive protein (CRP) and neutrophil ratio (NER), suggesting that the more severe the infection HP infection MESHD, the more obvious the early renal injury. Hypokalemia MESHD Hypokalemia HP and hyponatremia MESHD hyponatremia HP were common in patients with COVID-19, and there was a correlation with the degree of renal injury. Conclusions Early renal injury was common in patients with COVID-19. Combined detection of UMA, A1M, IGU, and TRU was helpful for the diagnosis of early renal injury in COVID-19.

    Mortality of COVID-19 is Associated with Cellular Immune Function Compared to Immune Function in Chinese Han Population

    Authors: Qiang Zeng Sr.; Yong-zhe Li Sr.; Gang Huang Sr.; Wei Wu Sr.; Sheng-yong Dong Sr.; Yang Xu

    doi:10.1101/2020.03.08.20031229 Date: 2020-03-10

    In December 2019, novel coronavirus (SARS-CoV-2) infected pneumonia MESHD pneumonia HP occurred in Wuhan, China. The number of cases has increased rapidly but information on the clinical characteristics of SARS-CoV-2 pneumonia MESHD pneumonia HP compared to normal controls in Chinese Han population is limited. Our objective is to describe the clinical characteristics of SARS-CoV-2 pneumonia MESHD pneumonia HP compared to normal controls in the Chinese Han population. In this case series of 752 patients, the full spectrum of cases is described. Fever MESHD Fever HP was present in 86-90% of the patients. The second most common symptom was cough MESHD cough HP (49.1-51.0%), fatigue MESHD fatigue HP (25.2-27.1%), sputum (20.0-23.1%), and headache MESHD headache HP (9.8-11.1%). the mortality rate is 4.6% in Wuhan, 1.9% in Beijing, and 0.9% in Shanghai. Our findings showed that the levels of lymphocytes were 0.8(IQR, 0.6-1.1)109/L in Wuhan, 1.0(IQR, 0.7-1.4)109/L in Beijing, and 1.1 (IQR, 0.8-1.5) 109/L in Shanghai before admission to hospitals, respectively, indicating that cellular immune function might relate to the mortality. Based on the reference ranges of normal Chinese Han population and the data of the critically ill patients we have observed, it is recommended that reference ranges of people at high risk of COVID-19 infection MESHD are CD3+ lymphocytes below 900 cells/mm3, CD4+ lymphocytes below 500 cells/mm3, and CD8+ lymphocytes below 300 cells/mm3.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv and is updated on a daily basis (7am CET/CEST).

Annotations

All
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as Endnote